Ionis Pharmaceuticals IONS Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's stock issuance proceeds?
- Ionis Pharmaceuticals (IONS) reported stock issuance proceeds of $57.3M in Q1 2026.
- How has Ionis Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Ionis Pharmaceuticals's stock issuance proceeds increased by 2457.0% year-over-year, from $2.24M to $57.3M.
- What is the long-term trend for Ionis Pharmaceuticals's stock issuance proceeds?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $11.57M to $0.
- What does stock issuance proceeds mean?
- Cash received from selling company shares.
- How do you interpret stock issuance proceeds?
- High inflows indicate successful equity fundraising or employee participation in stock plans, though it may signal potential dilution for existing shareholders.
- How does stock issuance proceeds compare across companies?
- Standard financing activity for growth-stage companies.